Design Therapeutics (DSGN) Income from Continuing Operations (2020 - 2026)

Design Therapeutics has disclosed Income from Continuing Operations across 7 years of filings, most recently posting 17636000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 17636000.0, changed 0.45% year-over-year; the trailing twelve-month figure through Mar 2026 was 69713000.0 (down 24.05% YoY), and the FY2025 annual result was 69792000.0, down 40.74% from the prior year.
• Income from Continuing Operations came in at 17636000.0 for Q1 2026 at Design Therapeutics, down from 15997000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 11105000.0 in Q1 2024 to a low of 22596000.0 in Q2 2023.
• The 5-year median for Income from Continuing Operations is 16997000.0 (2025), against an average of 16635235.29.
• Across the five-year window, Income from Continuing Operations sank 135.39% in 2022 and jumped 48.71% in 2024, its largest moves.
• Design Therapeutics' Income from Continuing Operations stood at 19392000.0 in 2022, then climbed by 22.02% to 15121000.0 in 2023, then grew by 9.72% to 13651000.0 in 2024, then declined by 17.19% to 15997000.0 in 2025, then declined by 10.25% to 17636000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 17636000.0 (Q1 2026), 15997000.0 (Q4 2025), and 16997000.0 (Q3 2025), per Business Quant data.